Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by MasterAlgaeon Aug 03, 2021 7:55pm
347 Views
Post# 33646427

RE:RE:Did you think 5x Liver Enzymes is Serious?

RE:RE:Did you think 5x Liver Enzymes is Serious?
It is incredibly serious. It is 500% higher than normal. Even if it is alcohol related that is a major danger for this arthritis drug.
 
The entire pipeline is all hydrogen sulphide...
 
The press release said that further research is warranted on the formulation of the drug. That's Serious.
 
"these findings indicate that further research is warranted with respect to both the optimal dose range and potential improvements to the formulation. These efforts will impact the plan for the Phase III program."

It absolutely impacts their position with partnering in a serious negative way...

It is not inconceivable that Antibe is circling the drain.

RalphRalph wrote: It's serious in the sense that it's going to delay Phase 3 and potentially alter their dosing strategy. It also undoubtedly has a negative impact on investor confidence, and certainly doesn't help the company negotiating position with big Pharma.  It also creates a significant amount of uncertainty about numerous aspects of the path forward


mstrmnd wrote: It's not...especially when higher doses are safe, therefore it's not dose-dependent

If up to 10% of patients on NSAIDS can have liver enzyme elevation normally, then we would expect at least 4 participants from the 42 person AME to have some degree of liver enzyme elevation...

Once everyone starts selling, can't stop irrational behaviour particularly when fear sets in...

New Buyers - Do your own DD - GLTA




<< Previous
Bullboard Posts
Next >>